We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on...
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology...
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases...
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate VANCOUVER, British...
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers VANCOUVER, British...
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer Pursuant to the terms of the licensing agreement...
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage...
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4 | -3.44827586207 | 11.6 | 11.8 | 11.1 | 233 | 11.8 | DE |
4 | 0.2 | 1.81818181818 | 11 | 11.8 | 11 | 603 | 11.32799668 | DE |
12 | 2.2 | 24.4444444444 | 9 | 11.8 | 8.9499999 | 529 | 10.10873578 | DE |
26 | 1.522 | 15.7263897499 | 9.678 | 11.8 | 7.75 | 494 | 8.98438102 | DE |
52 | 5.14 | 84.8184818482 | 6.06 | 12.045 | 5.876 | 554 | 8.81818734 | DE |
156 | 4.436 | 65.5824955648 | 6.764 | 12.045 | 5.876 | 559 | 8.74016851 | DE |
260 | 4.436 | 65.5824955648 | 6.764 | 12.045 | 5.876 | 559 | 8.74016851 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions